Nicolas Petit

HIV, Humanized mice

Gilles Marodon	grad student	2014	UPMC Univ Paris 6
(Etude pré-clinique d'une stratégie de thérapie génique de l'infection par le VIH combinant l'expression de deux inhibiteurs d'entrée)

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Burlion A, Brunel S, Petit NY, et al. (2017) Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model. Frontiers in Immunology. 8: 756
Petit N, Marodon G. (2016) Lessons From HIV-1 Gene Therapy in Humanized Mice: Is Targeting Viral Entry the Road to Success? Current Gene Therapy. 16: 56-64
Petit NY, Baillou C, Burlion A, et al. (2016) Gene transfer of two entry inhibitors protects CD4⁺ T cell from HIV-1 infection in humanized mice. Gene Therapy. 23: 144-150
Petit NY, Lambert-Niclot S, Marcelin AG, et al. (2015) HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice. Plos One. 10: e0138420
Petit N, Dorgham K, Levacher B, et al. (2014) Targeting both viral and host determinants of human immunodeficiency virus entry, using a new lentiviral vector coexpressing the T20 fusion inhibitor and a selective CCL5 intrakine. Human Gene Therapy Methods. 25: 232-40
Pham HP, Manuel M, Petit N, et al. (2012) Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice. European Journal of Immunology. 42: 760-70